Scancell (SCLP) Share Price, News & Analysis

Company Overview

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

Key Stats

• Today's Range: 9.50 to 11
• 50-Day Range: 9 to 12
• 52-Week Range: 7.26 to 19.75
• Volume: 1.03 million shs
• Average Volume: 862,018 shs
• Market Capitalization: £100.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCLP Stock Analysis - Frequently Asked Questions

How have SCLP shares performed this year?

Scancell's stock was trading at GBX 10.85 at the start of the year. Since then, SCLP shares have decreased by 10.6% and is now trading at GBX 9.70.
View the best growth stocks for 2025 here.

How were Scancell's earnings last quarter?

Scancell Holdings plc (LON:SCLP) released its earnings results on Thursday, January, 30th. The company reported ($1.35) EPS for the quarter.

How do I buy shares of Scancell?

Shares of SCLP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Scancell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scancell investors own include KAZ Minerals (KAZ), Petropavlovsk (POG), Standard Chartered (STAN), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO) and Empyrean Energy (EME).

Company Calendar

• Last Earnings: 1/30/2025
• Today: 6/25/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:SCLP
• CIK: N/A
• Web: www.scancell.co.uk
• Phone: +44-115-8231863
• Fax: N/A
• Employees: 51
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£6.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 98.74%
• Return on Assets: -45.28%

Debt

• Debt-to-Equity Ratio: -566.79
• Current Ratio: 3.42
• Quick Ratio: 13.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 1.24 per share
• Price / Cash Flow: 7.86
• Book Value: GBX (0.39) per share
• Price / Book: -24.91

Miscellaneous

• Outstanding Shares: 1,035,724,932
• Free Float: N/A
• Market Cap: £100.58 million
• Optionable: Not Optionable
• Beta: 0.35